Evinova, a new health-tech business launched by AstraZeneca, aims to revolutionize the clinical trial design and study delivery industry. The Anglo-Swedish pharmaceutical giant intends to offer solutions at scale to trial sponsors, clinical research organizations, care teams, and patients.
Evinova’s offerings will include improved data collection and machine learning algorithms to support teams designing their studies. The goal is to reduce the time and cost of developing new medicines, bring care closer to home for patients, and lessen the burden on health systems. To expand its reach, Evinova has announced major collaborations with clinical research organizations Parexel and Fortrea.
AstraZeneca’s Chief Executive, Pascal Soriot, expressed confidence in Evinova’s ability to make a significant impact on patient care, healthcare transformation, and carbon emissions reduction. The company also highlighted the expected growth of the digital-health market, projecting it to be worth more than $900 billion by 2032.
For more information on Evinova or AstraZeneca’s digital health solutions, contact Michael Susin at michael.susin@wsj.com
